At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 349 enrolled
Drug / intervention
Chemotherapy +1 moredrug
Likely dose
Rucaparib 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
In Brief
A Phase 3 clinical trial evaluating Chemotherapy and Rucaparib for Ovarian Cancer and 3 related conditions. Completed, enrolled 349 participants across 77 sites in 12 countries.
Detailed Summary
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBrazil, Canada, Czechia, Hungary, Israel, Italy, Poland, Russia, Spain, Ukraine, United Kingdom, United States
CollaboratorsFoundation Medicine
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartMar 2017
Primary CompletionDec 2020
Study CompletionSep 2022
TodayJul 2026
First PostedAug 4, 2016
Enrollment StartMar 1, 2017
Primary CompletionDec 3, 2020
Study CompletionSep 16, 2022
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 9.9 years ago
Interventions
Chemotherapydrug
Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
Rucaparibdrug
Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice a day